Oral News and Research

RSS

China Pharma Holdings announces completion of clinical trials for Candesartan

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that the Company has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production application to the SFDA.

21 Jan 2010

Osteoporosis-related event of 2010 to be held in Florence, Italy

Don't miss the most important osteoporosis-related event of 2010, to be held in the center of Florence, Italy from May 5 to 8, 2010.

21 Jan 2010

Results of two pivotal Phase III clinical trials with oral FTY720 published

Results of the TRANSFORMS and FREEDOMS studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine, providing comprehensive evidence to support the efficacy and safety profile of this first-in-class therapy for multiple sclerosis (MS).

21 Jan 2010

USPTO issues Notice of Allowance for IntelGenx's bupropion patent

IntelGenx Corp. ("IntelGenx") today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a formal Notice of Allowance for a key patent application protecting IntelGenx's CPI-300, a novel, high strength formulation of bupropion hydrochloride ("HCl"), the active ingredient in Wellbutrin XL(R).

21 Jan 2010

COTI's novel small molecule effective against pancreatic cancer in animal model

Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.

21 Jan 2010

EMD Serono announces results from CLARITY Phase III trial in MS patients

EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).

21 Jan 2010

Lupin's Mandideep facility receives FDA clearance

Pharma major, Lupin Ltd announced today that it has received official communication from the US FDA on the satisfactory resolution of the Warning Letter issued earlier to its Mandideep site. The company had received a Warning letter for its Mandideep site in May 2009. In the ensuing seven months, the company made significant enhancements and took appropriate corrective actions.

21 Jan 2010

Medco Health Solutions launches Medco TRC for oncology patients

Medco Health Solutions, Inc. today announced the launch of the Medco Therapeutic Resource Center® (TRC) for oncology patients headquartered in Whitestown, Ind., where specialist pharmacists will manage the company's more than 850,000 patients currently living with cancer, one of the fastest growing segments of healthcare.

21 Jan 2010

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled "Compositions and methods for enzymatic detachment of bacterial and fungal biofilms" by IP Australia (Australian Patent and Trademark Office).

21 Jan 2010

New review highlights risks and benefits of fluoride toothpaste in young children

Everyone who has ever seen a toothpaste commercial knows that fluoride is the ingredient that helps fight tooth decay, but a new review has determined exactly how much fluoride is best in toothpastes for children.

21 Jan 2010

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).

20 Jan 2010

Parents advised to use fluoridated toothpaste to prevent tooth decay in their children

Parents should use toothpastes that contain fluoride with a minimum concentration of 1,000 parts per million to prevent tooth decay in their children, says a new report. Preventing tooth decay can help reduce the need for extensive and costly dental treatments, including extractions.

20 Jan 2010

PROLOR Biotech's hGH-CTP Phase I study data to be presented at the BIO CEO & Investor Conference

PROLOR Biotech, Inc., today announced that final data from a randomized, dose-escalating Phase I clinical study of its longer-acting version of human growth hormone (hGH-CTP) will be featured in an oral presentation by PROLOR management at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel in New York City on February 8-9, 2010.

20 Jan 2010

Impact of life style factors on natural and medically assisted reproduction

The European Society of Human Reproduction and Embryology (ESHRE) has published a position statement on the impact of the life style factors obesity, smoking and alcohol consumption on natural and medically assisted reproduction.

20 Jan 2010

Antibiotics can reduce infections post-Caesarean section

Having a baby by Caesarean section is becoming increasingly common, despite the higher risks associated with the surgery compared to a vaginal birth. One important concern is the risk of infection, which is between five and 20 times greater for women who undergo scheduled or emergency Caesarean section.

20 Jan 2010

Access Pharmaceuticals provides update on its Cobalamin insulin development program

ACCESS PHARMACEUTICALS, INC. provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body's natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism.

20 Jan 2010

Patient enrollment for Phase 2B clinical study of Oramed Pharmaceuticals' ORMD-0801 completed

Oramed Pharmaceuticals Inc. announced today the completion of patient enrollment in the Phase 2B clinical study of its oral insulin capsule, ORMD-0801.

20 Jan 2010

Antibiotic drops are safe and effective for treating swimmer's ear

When treating the pain and inflammation of swimmer's ear, antibiotic drops are the most effective — and safest - therapy, finds a new review of studies.

20 Jan 2010

California limits HMO wait times

The regulations by the California Department of Managed Health Care, in the works for much of the last decade, will require that patients be treated by HMO doctors within 10 business days of requesting an appointment, and by specialists within 15.

19 Jan 2010

Novartis obtains exclusive worldwide rights to develop and commercialize Chiasma's TPE technology

Chiasma, Inc., a privately held biopharma company, announced today that it has granted Novartis an option to obtain exclusive worldwide rights to develop and commercialize the Company's Transient Permeability Enhancer (TPE) technology for use with certain related small molecule products either in development or currently marketed by Novartis.

19 Jan 2010

Oral News and Research

China Pharma Holdings announces completion of clinical trials for Candesartan

Osteoporosis-related event of 2010 to be held in Florence, Italy

Results of two pivotal Phase III clinical trials with oral FTY720 published

USPTO issues Notice of Allowance for IntelGenx's bupropion patent

COTI's novel small molecule effective against pancreatic cancer in animal model

EMD Serono announces results from CLARITY Phase III trial in MS patients

Lupin's Mandideep facility receives FDA clearance

Medco Health Solutions launches Medco TRC for oncology patients

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

New review highlights risks and benefits of fluoride toothpaste in young children

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Parents advised to use fluoridated toothpaste to prevent tooth decay in their children

PROLOR Biotech's hGH-CTP Phase I study data to be presented at the BIO CEO & Investor Conference

Impact of life style factors on natural and medically assisted reproduction

Antibiotics can reduce infections post-Caesarean section

Access Pharmaceuticals provides update on its Cobalamin insulin development program

Patient enrollment for Phase 2B clinical study of Oramed Pharmaceuticals' ORMD-0801 completed

Antibiotic drops are safe and effective for treating swimmer's ear

California limits HMO wait times

Novartis obtains exclusive worldwide rights to develop and commercialize Chiasma's TPE technology

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News